- Home
- DAWN vs TFIN Comparison
DAWN vs TFIN Comparison
Compare DAWN & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- TFIN
- Stock Information
- Founded
- DAWN 2018
- TFIN 1981
- Country
- DAWN United States
- TFIN United States
- Employees
- DAWN N/A
- TFIN N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- TFIN Major Banks
- Sector
- DAWN Health Care
- TFIN Finance
- Exchange
- DAWN Nasdaq
- TFIN Nasdaq
- Market Cap
- DAWN 1.2B
- TFIN 1.5B
- IPO Year
- DAWN 2021
- TFIN N/A
- Fundamental
- Price
- DAWN $8.07
- TFIN $58.80
- Analyst Decision
- DAWN Strong Buy
- TFIN Hold
- Analyst Count
- DAWN 7
- TFIN 6
- Target Price
- DAWN $32.29
- TFIN $77.50
- AVG Volume (30 Days)
- DAWN 1.3M
- TFIN 196.0K
- Earning Date
- DAWN 05-05-2025
- TFIN 04-16-2025
- Dividend Yield
- DAWN N/A
- TFIN N/A
- EPS Growth
- DAWN N/A
- TFIN N/A
- EPS
- DAWN N/A
- TFIN 0.54
- Revenue
- DAWN $131,161,000.00
- TFIN $396,285,000.00
- Revenue This Year
- DAWN $28.72
- TFIN $17.60
- Revenue Next Year
- DAWN $73.78
- TFIN $12.72
- P/E Ratio
- DAWN N/A
- TFIN $113.48
- Revenue Growth
- DAWN N/A
- TFIN N/A
- 52 Week Low
- DAWN $7.88
- TFIN $58.07
- 52 Week High
- DAWN $18.07
- TFIN $110.58
- Technical
- Relative Strength Index (RSI)
- DAWN 36.05
- TFIN 31.73
- Support Level
- DAWN $7.93
- TFIN $60.76
- Resistance Level
- DAWN $8.44
- TFIN $65.64
- Average True Range (ATR)
- DAWN 0.44
- TFIN 2.87
- MACD
- DAWN 0.09
- TFIN 0.58
- Stochastic Oscillator
- DAWN 17.59
- TFIN 9.64
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.